Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanomi specializes in the development and manufacture of precisely defined microspheres and nanoparticles for long-term drug delivery using its proprietary Microsieve/Monosphere Technology. This enables highly controlled production of biodegradable particles that encapsulate active pharmaceutical ingredients for sustained-release injectables. The company operates as a subsidiary of Lupin since its acquisition in 2014 and partners with pharma/biotech companies to enable advanced drug delivery solutions but does not market products under its own name.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanomi.